These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19538116)

  • 1. Economic evaluations of hepatitis B vaccination for developing countries.
    Tu HA; Woerdenbag HJ; Kane S; Riewpaiboon A; van Hulst M; Postma MJ
    Expert Rev Vaccines; 2009 Jul; 8(7):907-20. PubMed ID: 19538116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).
    Beutels P
    Health Econ; 2001 Dec; 10(8):751-74. PubMed ID: 11747055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).
    La Torre G; Mannocci A; Saulle R; Colamesta V; Meggiolaro A; Mipatrini D; Sinopoli A
    Hum Vaccin Immunother; 2016 Sep; 12(9):2299-311. PubMed ID: 27105443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluations applied to HB vaccination: general observations.
    Beutels P
    Vaccine; 1998 Nov; 16 Suppl():S84-92. PubMed ID: 9915046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.
    Boccalini S; Taddei C; Ceccherini V; Bechini A; Levi M; Bartolozzi D; Bonanni P
    Hum Vaccin Immunother; 2013 May; 9(5):1119-28. PubMed ID: 23376840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
    Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
    Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluations of hepatitis A vaccination in middle-income countries.
    Suwantika AA; Yegenoglu S; Riewpaiboon A; Tu HA; Postma MJ
    Expert Rev Vaccines; 2013 Dec; 12(12):1479-94. PubMed ID: 24168129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model.
    Aggarwal R; Ghoshal UC; Naik SR
    J Hepatol; 2003 Feb; 38(2):215-22. PubMed ID: 12547411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.
    Holliday SM; Faulds D
    Pharmacoeconomics; 1994 Feb; 5(2):141-71. PubMed ID: 10146907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board.
    Van Damme P; Kane M; Meheus A
    BMJ; 1997 Apr; 314(7086):1033-6. PubMed ID: 9112852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is universal better than selective immunization in developing world? Vaccines (HBV).
    Boyles S
    Hepatitis Wkly; 1998 Oct; ():7-8. PubMed ID: 12294767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa.
    Edmunds W; Dejene A; Mekonnen Y; Haile M; Alemnu W; Nokes D
    Health Policy Plan; 2000 Dec; 15(4):408-16. PubMed ID: 11124244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cohesive European policy for hepatitis B vaccination, are we there yet?
    Lernout T; Hendrickx G; Vorsters A; Mosina L; Emiroglu N; Van Damme P
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():19-24. PubMed ID: 24829936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Vaccine in national immunization schedule: a preventive step in India.
    Verma R; Khanna P; Prinja S; Rajput M; Chawla S; Bairwa M
    Hum Vaccin; 2011 Dec; 7(12):1387-8. PubMed ID: 22134433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.